VRB-104 / Verdiva Bio - LARVOL DELTA

Characterization and Preclinical Efficacy of a Novel Unimolecular Amylin and GLP-1 Receptor Dual Agonist, VRB-104 (ADA 2026) - "VRB-104 is a novel unimolecular amylin & GLP-1 receptor dual agonist, with selectivity for hAMY3R over GLP-1R. These data support the continued development of VRB-104 for the treatment of obesity and type 2 diabetes."

Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Title: Characterization and Preclinical Efficacy of a Novel Unimolecular Amylin and GLP-1 Receptor Dual Agonist, VRB-104 (Businesswire) - "In cell culture, VRB-104 demonstrated nearly 3-fold increased potency on hAMY3R and 9-fold reduced potency on GLP-1R, when compared to amycretin; In a diet-induced obesity model, daily dosing of VRB-104 for 14 days resulted in 14% body weight loss from baseline, compared to 1% weight gain in vehicle; VRB-104 is a novel unimolecular amylin and GLP-1 receptor dual agonist and has demonstrated selectivity for hAMY3R over GLP-1R. Reduced GLP-1R potency and increased AMY3 potency was incorporated into the design of VRB-104 with the goal of maintaining clinical efficacy while potentially reducing GLP-1 associated adverse events. These data support the continued development of VRB-104 for the treatment of obesity."

Preclinical • Obesity

Verdiva Bio to Present Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions (Businesswire) - "The presentations include new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular GLP-1 plus amylin co-agonist."

Preclinical • Obesity